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combined infusion concurrent with
radiation therapy in advanced oral cancersBengGwan Teh*, Wataru Kobayashi, Kenji Narita,
Roh Fukui, Hiroto KimuraDepartment of Oral and Maxillofacial Surgery, Hirosaki University School of Medicine,
5-Zaifu-cho, Hirosaki, Aomori 036-8562, JapanReceived 25 August 2004; accepted 26 August 2004Summary Cisplatin-based superselective intra-arterial chemotherapy concurrent
with radiotherapy (SIART) has been reported to be effective in advanced head
and neck carcinomas (HNC). However, the ideal regimen has not been established.
We combined nedaplatin (CDGP) with docetaxel (DOC) as a new combination in
SIART for treatment of advanced oral squamous cell carcinomas (OSCC). Two
patients with stage IV advanced OSCC were treated and complete response (CR)
were attained, although a residual metastatic lymph node remained in one case.
Thirteen and 10months post-treatment, no recurrence or metastatic spread was
observed. This result indicated that CDGP and DOC combination in SIART is effective
in advanced OSCC treatment.c 2004 Elsevier Ltd. All rights reserved.
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Chemotherapy, radiotherapy and surgery are the
main treatment of the head and neck carcinomas741-9409/$ - see front matter c 2004 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2004.08.002
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E-mail address: mteh70@hotmail.com (BG. Teh).(HNC). Although combination of surgery and radio-
therapy is considered to be a standard treat-
ment,1,2 outcome of HNC therapy is not
satisfactory in term of survival rates particularly
in patients with stages III and IV advanced neo-
plasm.3,4 Furthermore, in weighing the cost-bene-
fit of treatment, organ preservation in treatment
of advanced HNC is another important considera-
tion for quality of life (QOL).5ved.
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lective intra-arterial chemotherapy concurrent
with radiotherapy (SIART) has become popular
in advanced HNC treatment.6,7 Cisplatin (CDDP)
together with docetaxel (DOC) have been reported
to be the ideal chemotherapeutic agents.8–12
Recently, nedaplatin (CDGP), an analogue of cisp-
latin with less toxicity, was reported to be effec-
tive for HNC treatment.13,14
The purpose of this report is to describe the effi-
cacy of two agents, DOC and CDGP as a new combi-
nation in SIART, used in the treatment of two cases
of T4 advanced oral squamous cell carcinomas
(OSCC), where complete response (CR) was ob-
tained in the primary region with no consequent
surgical procedure.Figure 1 Pre-treatment extra (A) and intra-oral photograp
the tumor invasion (arrows).Report of cases
Treatment procedure
After the assessment of the tumor invasion ex-
tent by computed tomography (CT) and magnetic
resonance imaging (MRI), selection of the feeding
arteries of the tumor by CT angiography (CTA)
and digital subtraction angiography (DSA) via femo-
ral artery was conducted. A total of 66Gy of irradi-
ation was initiated for a period of seven weeks
concurrent with three courses of DOC (60mg/body)
and CDGP (80mg/m2) combination of chemothera-
peutic agent infusion. After final evaluation by
radiographic examination and incisional biopsyh (B). (C) Computed tomography revealed the extent of
128 BG. Teh et al.the patients were discharged as no residual tumor
was found in the primary region.
Case 1
A 45-year-old woman diagnosed with advanced
OSCC was referred to our department. The patient
facial countenance was asymmetrical as the result
of right facial induration by palpable tumor but no
skin invasion was observed. Metastatic lymph nodes
(mLN) were identified bilaterally in the superior-
internal-jugular region. Fig. 1 shows the photo-
graphs and enhanced-CT of the patient. A T4N2c
poorly differentiated OSCC of the right gingival of
the mandible was diagnosed after incisional biopsyFigure 2 (A) DSA of the feeding arteries. Arrows indicate th
post-treatment, and (C) computed tomography where residuwas performed. SIART was opted for the treatment
where selection of the feeding arteries (facial, lin-
gual, infra-alveolar and ascending pharyngeal) was
determined by CTA and DSA (Fig. 2A). After three
courses of the combined treatment, CR was
obtained in the primary site although a reduced
size mLN remained at the right superior-internal-
jugular region. Radical neck dissection was planned
but the patient declined to undergo operation. The
patient was discharged four months after admis-
sion and observation is carried out with chemother-
apeutic medication prescribed. Thirteen months
post-treatment, no primary recurrence or progres-
sion of the residual mLN was observed (Fig. 2B
and C).e staining extent of the tumor. (B) Clinical view 13months
al metastatic lymph node is observed (arrow).
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A 47-year-old woman with swelling of the sub-
mental region and a swollen tongue was referredFigure 3 (A) Swelling at submental region. (B) Pre-treatm
tomography and magnetic resonance imaging (D). Arrows ind
Figure 4 Ten months post-treatment. Extra-oral (A) and
computed tomography.to our department (Fig. 3). A T4N2a well-differen-
tiated OSCC of the tongue was diagnosed by radiog-
raphy and incisional biopsy and the patient opted
for SIART. The feeding arteries were just the sameent intra-oral photograph. (C) Pre-treatment computed
icate the tumor invasion extent.
intra-oral photograph (B). (C) No tumor observed in
130 BG. Teh et al.as in case 1. After three courses of the combined
therapies, no residual tumor was observed. There
was no evidence of recurrence or metastatic
spread either at the primary site or in the neck
10months post-treatment (Fig. 4).Discussion
For the last decade, SIART has been extensively
conducted and has become a common and effec-
tive therapy in advanced HNC.6,7,15,16 Although var-
ious chemotherapeutic agents have been tried,
there is still no consistently dependable regimen
available. Numerous CDDP based-regimens have
been cited as effective in HNC treatment,8,9,17,18
although severe nephrotoxicity, mucositis, nausea
and anorexia develop in some cases and treatment
has to be suspended.
CDGP, an analogue of CDDP, was developed re-
cently and reported to be as effective or superior
to CDDP in treatment of HNC.13,14 The pH of CDGP
was 7.0 and did not caused angialgia during the
infusion and no neutralizer was needed. Renal
toxicity is rare where post-treatment hydration is
limited. Although more severe myelotoxicity par-
ticularly thrombocytopenia was observed, CDGP
has fewer gastrointestinal symptoms and treat-
ment suspension due to the side effects was not
reported.14
In this paper, two cases of T4 advanced OSCC are
reported who were treated by SIART using a combi-
nation of CDGP and DOC. DOC, a taxane, has sign-
ificant response reported in HNC,10 and the
mechanism of action against tumor cells was
totally different from CDDP. In both cases CR was
obtained in the primary region, although residual
mLN remained in case 1. Besides clinical examina-
tion, CT and MRI post-treatment were conducted to
assess the treatment effect. Incisional biopsy was
taken and no viable cells were identified.
Advanced OSCC tend to have more than one
feeding artery and trans-femoral artery approach
has the advantage of administrating the chemo-
therapeutic agents to multiple arteries feeding
the tumor, as compared to conventional SIART.
However, it is hard to obtain a good response rate
in mLN because the feeding arteries are compli-
cated and difficult to locate. Therefore, neck dis-
section is considered to be appropriate for cases
where mLN were confirmed.19
The side effects of treatment in the two cases
included a grade II reverse hemicranial alopecia,
a grade III neutropenia, where reversion of the neu-
trophil count was achieved after injection of G-CSF, and a grade III mucositis requiring no interrup-
tion of irradiation. No thrombocytopenia was
observed, although mild to severe thrombocytope-
nia has been reported in cases where CDGP was
administrated independently.14 Both patients con-
tinued oral diet during the treatment period with
good pain-control gained by using analgesic of
NSAID and morphine.
In conclusion, the regimen of DOC and CDGP
combination of chemotherapeutic agents used in
SIART showed a good response where CR was ob-
tained in treatment of advanced OSCC with man-
ageable toxicities. No relapse of tumors and no
progression or spreading of mLN was evident in
the two cases 13 and 10months post-treatment.
At least four weeks of interval period was needed
between the SIA chemotherapies due to the devel-
opment of neutropenia from DOC and CDGP, which
prolonged the treatment period for more than
three months.References
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